Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatorenal syndrome treated for eight months with continuous-flow peritoneal dialysis.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2013
Same author

Year in review 2012: Critical Care--Nephrology.

Critical care (London, England)·2013
Same author

Healthcare systems and chronic kidney disease: putting the patient in control.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2013
Same author

Neutrophil gelatinase associated lipocalin in acute kidney injury.

Postgraduate medicine·2013
Same author

Ultrafiltration therapy for acute decompensated heart failure: lessons learned from 2 major trials.

American heart journal·2013
Same author

Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference.

Kidney international·2013

Related Experiment Video

Updated: Jun 5, 2026

Creating Radio-cephalic Arteriovenous Fistula in the Forearm with a Modified No-Touch Technique
07:30

Creating Radio-cephalic Arteriovenous Fistula in the Forearm with a Modified No-Touch Technique

Published on: April 1, 2022

Arteriovenous fistula toxicity.

Richard Amerling1, Claudio Ronco, Martin Kuhlman

  • 1Department of Internal Medicine-Nephrology, Vivantes Klinikum im Friedrichshain, Berlin, Germany. ramerlin@chpnet.org

Blood Purification
|January 14, 2011
PubMed
Summary

Arteriovenous fistulas (AVF) are preferred for hemodialysis but have significant toxicity, including primary failure and serious complications. Current guidelines may overlook AVF risks, potentially leading to adverse outcomes.

More Related Videos

A Novel Murine Model of Arteriovenous Fistula Failure: The Surgical Procedure in Detail
10:10

A Novel Murine Model of Arteriovenous Fistula Failure: The Surgical Procedure in Detail

Published on: February 3, 2016

Technical Aspects of the Mouse Aortocaval Fistula
06:12

Technical Aspects of the Mouse Aortocaval Fistula

Published on: July 11, 2013

Related Experiment Videos

Last Updated: Jun 5, 2026

Creating Radio-cephalic Arteriovenous Fistula in the Forearm with a Modified No-Touch Technique
07:30

Creating Radio-cephalic Arteriovenous Fistula in the Forearm with a Modified No-Touch Technique

Published on: April 1, 2022

A Novel Murine Model of Arteriovenous Fistula Failure: The Surgical Procedure in Detail
10:10

A Novel Murine Model of Arteriovenous Fistula Failure: The Surgical Procedure in Detail

Published on: February 3, 2016

Technical Aspects of the Mouse Aortocaval Fistula
06:12

Technical Aspects of the Mouse Aortocaval Fistula

Published on: July 11, 2013

Area of Science:

  • Nephrology and Vascular Surgery
  • Dialysis Access and Complications

Background:

  • Arteriovenous fistulas (AVF) have been the gold standard for hemodialysis access since the 1960s.
  • AVFs are favored for their durability and lower infection rates compared to other access methods.

Purpose of the Study:

  • To highlight the underrecognized "toxicity" of arteriovenous fistulas.
  • To examine the significant primary failure rates and associated complications of AVFs.
  • To question current guidelines that may not adequately address AVF-related morbidity and mortality.

Main Methods:

  • Review of existing literature and clinical data on arteriovenous fistula outcomes.
  • Analysis of complications including primary failure, cardiac, and vascular issues.
  • Evaluation of current policy and guideline impact on AVF utilization and patient safety.

Main Results:

  • AVFs exhibit considerable primary failure rates.
  • Significant cardiac, vascular, and other complications contribute to AVF toxicity.
  • These complications are linked to substantial patient morbidity and mortality.

Conclusions:

  • Arteriovenous fistulas, despite their benefits, possess significant, often overlooked, toxicity.
  • Current clinical policies and guidelines may inadequately address AVF-related risks.
  • Increased AVF use driven by policy may lead to unintended negative patient consequences.